Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ

Recruiting now · Phase 2

Conditions studied: Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma

In brief

This study is a prospective, single-arm, phase II clinical study. Screening patients with stage III GC/GEJ adenocarcinoma after D2 or broader radical resection. After enrolling in the study, the subjects receive Sintilimab combined with oxaliplatin+Tegafur, Gimeracil and Oteracil Potassium Capsules (SOX) or oxaliplatin+Capecitabine (XELOX) , in which the combined chemotherapy is up to 8 cycles, and the total course of treatment was 16 cycles. The following-up of subjects includes adverse events、disease status、living conditions and the quality of life.

Key facts

Study ID
NCT06761846
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
People needed
70
Starts
2025-01-17
Expected to finish
2028-12-31
Last updated by the study team
2026-04-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.